- Idiopathic pulmonary fibrosis is a chronic, progressive fibrotic interstitial lung disease of unknown cause, characterized by worsening dyspnea and lung function. The increasing incidence of IPF, advancements in diagnostic tools, and growing awareness among physicians and patients are key factors driving the treatment market
- The demand for these microscopes is significantly driven by their disease-modifying potential and regulatory approvals in multiple regions
- North America holds the largest share in the global IPF treatment market, owing to the presence of major pharmaceutical players, favorable reimbursement policies, and strong R&D pipeline
- Asia-Pacific is anticipated to register the highest CAGR due to a growing aging population, increasing diagnostic rates, and improving healthcare infrastructure
- Tyrosine Inhibitors are expected to dominate the market in 2025 with the largest market share of 47.2%, driven by clinical efficacy in slowing disease progression and regulatory support
